GlassScriptPhysician profile
Richard C Phinney
NPI 1215192703
$12,507.02
in general payments reported to CMS, 2019-2025
29 companies · $3,083 in 2025
The $3,083 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $1,038 · 2021: $6,214 · 2022: $539 · 2024: $1,397 · 2025: $3,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,435 · Honoraria: $1,200 · Food and Beverage: $732 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,435.00 |
| Honoraria | $1,200.00 |
| Food and Beverage | $731.92 |
| Education | $113.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $6,160.95 | 2021-2022 | |
| Daiichi Sankyo INC. | $1,822.87 | 2020-2025 | Datroway |
| Pfizer INC. | $1,215.39 | 2021-2024 | |
| Incyte Corporation | $1,012.42 | 2025 | Jakafi, Jakafi, Monjuvi |
| Geron Corporation | $795.30 | 2025 | Rytelo |
| Astrazeneca Pharmaceuticals LP | $216.08 | 2019-2025 | Enhertu |
| Janssen Biotech, INC. | $177.97 | 2019-2025 | Erleada |
| E.R. Squibb & Sons, L.L.C. | $163.21 | 2022-2024 | |
| Tempus Ai, INC | $156.13 | 2024-2025 | Xt Cdx |
| Pinnacle Biologics, INC | $124.56 | 2024 | Photofrin |
| Eisai INC. | $100.59 | 2022 | |
| Dova Pharmaceuticals | $92.42 | 2020 | |
| Merck Sharp & Dohme LLC | $85.02 | 2021-2025 | Keytruda |
| Ipsen Biopharmaceuticals, INC | $75.29 | 2022 | |
| Novartis Pharmaceuticals Corporation | $65.74 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $45.37 | 2021-2025 | Tecentriq |
| Beone Medicines USA, INC. | $20.38 | 2025 | Brukinsa |
| Celgene Corporation | $19.31 | 2022 | |
| Seagen INC. | $19.16 | 2022 | |
| Puma Biotechnology, INC. | $17.45 | 2025 | |
| Amgen INC. | $14.59 | 2019 | |
| Morphosys, US INC. | $14.25 | 2022 | |
| Rigel Pharmaceuticals, INC. | $14.16 | 2021 | |
| Coherus Oncology, INC. | $14.07 | 2020 | |
| Foundation Medicine, INC. | $13.59 | 2022 | |
| Lilly USA, LLC | $13.34 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.08 | 2024 | Libtayo |
| Exelixis INC. | $12.41 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Phinney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.